Skip to main content



Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

*June 2021* Note: Most research in resistance has been studied in isolation, not accounting for the complexity tumor heterogeneity and the patient heterogeneity. This model was presented at one of the plenary sessions, considers the complex pharmacokinetics and variability of drug concentration in patients, specifically the change in concentrations of multiple…

Pivotal Trials Put HER2-Mutated NSCLC on Notice

*March 2022* Note: In this article,  Julien Mazieres, MD, PhD, talks R2D2, while Bob Li, MD, PhD, MPH, highlights DESTINY-Lung01 Also note: In the Destiny trial, Drug-related interstitial lung disease (ILD) and pneumonitis remain an important, identifiable risk. The R2D2 trial achieved a first by showing that HER2 mutations can be "treatable targets" in…

Concurrent TP53 mutations facilitate resistance evolution in EGFR mutant lung adenocarcinoma

*March 2022* PURPOSE Patients with EGFR-mutant non-small cell lung cancer (NSCLC) experience variable duration of benefit on EGFR tyrosine kinase inhibitors (TKI). The effect of concurrent genomic alterations on outcome has been incompletely described. MATERIAL AND METHODS In this retrospective study, targeted next-generation sequencing data was collected from patients with EGFR-mutant lung…

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)

*March 2022* Highlights: The EGFR-TKI efficacy of uncommon EGFR mutations generally considered TKI-sensitive was validated. Complex EGFR mutations containing exon19del or L858R mutations were EGFR TKI sensitive, independent of the combination partner. Very rare single and complex mutations, comprising 40% of atypical mutations, show a high heterogeneity of TKI sensitivity. TP53 co-mutations may confer…